Obinutuzumab + MMF + Prednisone + Methylprednisolone + Acetaminophen/ Paracetamol + Diphenhydramine Hydrochloride
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Childhood Idiopathic Nephrotic Syndrome
Conditions
Childhood Idiopathic Nephrotic Syndrome
Trial Timeline
Mar 29, 2023 → Sep 4, 2026
NCT ID
NCT05627557About Obinutuzumab + MMF + Prednisone + Methylprednisolone + Acetaminophen/ Paracetamol + Diphenhydramine Hydrochloride
Obinutuzumab + MMF + Prednisone + Methylprednisolone + Acetaminophen/ Paracetamol + Diphenhydramine Hydrochloride is a phase 3 stage product being developed by Roche for Childhood Idiopathic Nephrotic Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT05627557. Target conditions include Childhood Idiopathic Nephrotic Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05627557 | Phase 3 | Active |
Competing Products
20 competing products in Childhood Idiopathic Nephrotic Syndrome